R. Chiron

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

Michael W. Konstan, Patrick A. Flume, Matthias Kappler et al. · Journal of Cystic Fibrosis · 2010 · 313 citations

Pharmacy, Clinical Pharmacy, Pharmacotherapy +14

Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

Pierre‐Régis Burgel, I. Durieu, R. Chiron et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 235 citations

Medicine, Pharmacotherapy, Pulmonary Function Testing +15

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

Jean Bousquet, Antonio Addis, Ian M. Adcock et al. · European Respiratory Journal · 2014 · 170 citations · Full text

Medicine, Chronic Disease Prevention, Health Policy +17

A Proof-of-Concept, Randomized, Controlled Trial of Omalizumab in Patients With Severe, Difficult-to-Control, Nonatopic Asthma

Gilles Garcia, A. Magnan, R. Chiron · CHEST Journal · 2013 · 162 citations

Life Sciences, Immunology, Pharmacology +17

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial

B.M. Assael, Tacjana Pressler, Diana Bilton et al. · Journal of Cystic Fibrosis · 2012 · 136 citations

Medicine, Internal Medicine, Pharmacotherapy +12